Gene Editing & CRISPR stocks on X

Gene Editing & CRISPR stocks trending on X

Top stocks by X chatter

Precigen, Inc.$PGENStrong Fundamentals

Biotechnology

$6.93-0.29%

1Y+45.6%

74 posts+6%

Bullish sentiment

Precigen chatter is bullish. Contributors flag HPV+ cancer data next quarter — valuation could 'more than triple if data are positive (very likely).' CEO reiterating cash-flow positive by year-end and HPV platform validation. Director bought +25k at $7.23. Every pull-down 'a good buy this year' framing. Loud voices constructive on the pipeline + insider signal.

Hinges on a big event

Precigen is a gene-therapy company developing PRGN-2009 in HPV-driven cancers and other AdenoVerse-platform candidates. Shares are +53% TTM at $6.95, and the setup is a specific pipeline-catalyst play. • Revenue and EPS ramped: quarterly revenue ran $2.9M / $4.6M / $23.3M / $55.0M as PRGN-2009 revenue recognition began — that's a genuine inflection, and analysts model $232.9M of full-year revenue and $0.14 EPS as the base commercial ramp continues. • The HPV+ cancer data is the specific next catalyst: contributors flag HPV+ cancer data next quarter with valuation upside that could 'more than triple if data are positive (very likely)' — that's the shape of a name where the pipeline catalyst is the whole equity move. • Insider signal aligns with pipeline: a director bought +25k shares at $7.23 — meaningful insider conviction going into a dated catalyst, and CEO commentary reiterating cash-flow positive by year-end reinforces the operational stability. A positive HPV+ cancer data readout with additional PRGN-2009 commercial commentary extends the coil into a real repricing; a data slippage, a safety-signal disclosure, or a fresh dilutive equity raise is what invalidates the setup. The Nov 12 Q3 print will provide additional pipeline color, but the readout is the main event.

Krystal Biotech, Inc.$KRYSStrong Fundamentals

Biotechnology

$359.36+2.25%

1Y+141.2%

20 posts-21%

Bullish sentiment

Krystal Biotech posts frame Q2 as a pristine cash machine: revenue $119.2M up 24% year over year, net income $54.8M, gross margins at 95% and the balance sheet crossing $1.1B. VYJUVEK global revenue $119.2M and $965.9M since launch reinforce the durable-growth story, with brief pullback pressure.

Proven numbers

Krystal Biotech (KRYS) sits in a category almost no small-cap biotech reaches — profitable, commercial, and still with pipeline optionality. • Q2 EPS beat consensus by ~5% on continued VYJUVEK uptake for dystrophic epidermolysis bullosa, with international launches beginning to layer on top of the US base. • Beyond VYJUVEK, the KB-series pipeline (respiratory, oncology, ophthalmology) using the same HSV-based redosable-gene-therapy platform is the multi-year rerating lever. • A recent director S-Sale of ~$8.2M by Rossi on August 14 is the kind of headline that always spooks retail — worth noting, but on a name of this scale it is typically diversification rather than a conviction signal. Bottom line: commercial execution and pipeline breadth make this a bona fide fundamentals name in a space usually dominated by story stocks; watch VYJUVEK international ramp and KB-series readouts.

Fractyl Health, Inc.$GUTS

Biotechnology

$0.711+7.86%

1Y-27.2%

9 posts-11%

Bullish sentiment

Fractyl Health reports positive REMAIN-1 midpoint cohort data showing durable weight maintenance one year after GLP-1 discontinuation. H.C. Wainwright reiterates Buy PT $8, Morgan Stanley PT $2, with pivotal cohort data expected early Q4 and potential De Novo FDA submission late Q4. Approval seen ~80% derisked.

Hinges on a big event

Fractyl Health (GUTS) is a clinical-stage GLP-1/metabolic-disease company whose July 15 data pushed the equity into the middle of the obesity-durability debate. • REMAIN-1 Midpoint Cohort one-year data showed dose-dependent durability of weight maintenance after GLP-1 discontinuation for the Revita duodenal metabolic therapy device — a meaningful differentiator vs the injectable-only paradigm. • Q2 EPS of -$0.12 beat the -$0.14 estimate by ~11%; sell-side spread is wide (H.C. Wainwright Buy $8, Morgan Stanley $2), reflecting the binary-catalyst nature of the setup. • Multiple securities-class actions (Bronstein, Robbins, Levi & Korsinsky, October 20 lead-plaintiff deadline) create real headline risk that runs alongside the pivotal-data and De Novo FDA submission expected around late Q4. Bottom line: real durability signal in a scarce category, offset by legal overhang — this is a binary-catalyst trade with more upside than downside if pivotal reads cleanly.

Maravai LifeSciences Holdings, Inc.$MRVI

Biotechnology

$7.64-0.52%

1Y+222.4%

139 posts+4%

Bullish sentiment

Maravai LifeSciences posts are cautiously bullish, framing MRVI as a healthcare-space rotation beneficiary with strong entry tactics on catalyst + highest-volume-in-a-year (edge). Sample is thin with some skeptical outsider commentary; overall tone is opportunistic bullish.

Editas Medicine, Inc.$EDIT

Biotechnology

$3.06-3.16%

1Y+23.9%

54 posts-2%

Bullish sentiment

Editas Medicine chatter emphasizes ARKG's weekly chart showing the genomics theme starting to move strongly into end-of-year, with users citing the CRISPR history of $EDIT/$NTLA/$CRSP rallies as the analog. Posts describe EDIT as one of the main biotech themes for next week's watchlist. Chatter reads as sector-rotation-driven positioning ahead of a potential run.

BridgeBio Pharma, Inc.$BBIO

Biotechnology

$76.59-0.01%

1Y+53.2%

54 posts0%

Bullish sentiment

X is emphatically bullish on BridgeBio, with the ESC26 readout on Acoramidis driving the mood — posts cite CMR data showing 'reversal' of cardiac structural disease, sustained mortality benefit, and 'separation as early as 3 months' as reasons to hold. Bulls call it one of biotech's '4 horsemen' with three drug applications pending, while an ALNY-camp minority argues silencers make combo therapy the future.

uniQure N.V.$QURE

Biotechnology

$48.68-0.08%

1Y+186.2%

189 posts-1%

Bullish sentiment

The uniQure thread is loud and confidently long into a September catalyst window for AMT-130 in Huntington's disease. Posters lean on Dr. Victor Sung's KOL commentary that the four-year data separation could widen, a peer-reviewed paper expected imminently, 21.5% concentrated institutional ownership across seven of the top-25 biotech funds and about 10.7M shares short as squeeze fuel. Bears are visible but sparse, mostly noting that a filing acceptance alone may not move the stock. The base case is that BLA filing, UK application and four-year data all land before Q3 ends.

Twist Bioscience Corporation$TWST

Medical - Diagnostics & Research

$139-1.68%

1Y+429.7%

368 posts+31%

Bullish sentiment

The mood is bullish on Twist Bioscience — bulls frame it as the pick-and-shovel of AI drug discovery, with Claude-designed binders validating on Twist's high-throughput silicon DNA platform and biopharma programs moving from "tens of candidates" to hundreds or thousands across many targets. Chartists cheer an "extremely bullish" breakout of the 2022 base, and one holder ran a 3% starter at ~$25 to $146 today. Countering: Cathie Wood was a net seller ($3.5M of TWST) and one shortseller notes it is "expensive as hell here."

Allogene Therapeutics, Inc.$ALLO

Biotechnology

$2.00-0.99%

1Y+78.6%

242 posts+2%

Mixed sentiment

Almost all posts are technical crypto trading on the Allora token — traders flag a compression pattern near $0.256 with potential 88% upside, note short-crowded futures positioning, and debate wave counts. Sentiment on the token skews cautiously bullish around support but includes an outright short setup. A single biotech post frames ALLO alongside CRBU on off-the-shelf CAR-T, entirely unrelated to the crypto chatter.

Prime Medicine, Inc.$PRME

Biotechnology

$3.59-0.55%

1Y+15.1%

169 posts+4%

Bullish sentiment

Prime Medicine's thread turns emphatically bullish as posters flag zero short-shares-available on Fintel against 31-35M shares short and 10 days to cover, a break above the 50 and 200 EMA and mentions up 200% in four days. Bulls list the catalyst window: Wilson's first-in-human dosing, an AATD IND filing, additional CGD dosings and a potential BMY cash milestone. A few pleading posts fault management on the cash position; conviction otherwise dominates.

Vertex Pharmaceuticals Incorporated$VRTX

Biotechnology

$545.42+0.69%

1Y+35.8%

84 posts+5%

Bullish sentiment

Vertex Pharmaceuticals sentiment is confidently bullish. Users highlight VRTX strengthening in a healthcare rotation (with MRK/NEM/COP), Jim Lebenthal buying VRTX on Fast Money, and BBIO framed as the 'next VRTX'. RBC suggests VRTX might need to rely on Nav1.7 vs SGMO (interesting dynamic with LLY reportedly bidding on SGMO Nav1.7). Historical VRTX 1999 dot-com run cited as inspirational anchor. Skepticism is essentially absent; the modal stance is 'buy VRTX — rotation into pharma leaders'.

CRISPR Therapeutics AG$CRSP

Biotechnology

$56.98-1.28%

1Y+8.2%

199 posts+9%

Bullish sentiment

Sentiment is bullish and unusually catalyst-driven, revolving around the CTX310 ANGPTL3 data CRISPR Therapeutics presented at ESC 2026. Traders cite deep, durable one-year reductions in LDL and triglycerides after a single infusion, with the stock 'coiling beneath resistance' and multiple timeframes turning bullish. One caveat surfaces around 'hidden bearish divergence' on the weekly chart, but the dominant read is a biotech breakout waiting for a clean push through $61.

Intellia Therapeutics, Inc.$NTLA

Biotechnology

$12.73-1.09%

1Y+11.7%

99 posts-6%

Bullish sentiment

Chatter positions Intellia favorably in the ATTR-CM/PN gene-editing debate, with one poster asserting NTLA "showed the best data across the board in CM & PN" against ALNY, IONS and BBIO. The disagreement is intramural: bulls argue IONS's 69.7% TTR knockdown is "laughably horrible" versus the ~80% threshold ALNY established for stasis, and defend combo therapy over BBIO's stabilizer stance. Broader posts frame gene editing as eventually "capable of curing the majority of diseases."

WuXi AppTec Co., Ltd.$WUXIF

Medical - Diagnostics & Research

$24.950.00%

1Y+74.5%

0 posts

PendingInsufficient posts on X for reliable sentiment analysis.

Beam Therapeutics Inc.$BEAM

Biotechnology

$29.43+0.38%

1Y+80.4%

208 posts-7%

Mixed sentiment

The BEAM cashtag is fragmented across two different assets, and the chatter reflects that. The loudest voices are crypto traders celebrating a Beam gaming token spike on OrangeX/Bybit, alongside a smaller thread of Beam Therapeutics bulls citing a Wainwright reiterated Buy at $80 PT and admiration for founder David Liu. The equity signal is thin and mixed with token-pump noise rather than a coherent stock conversation.

Caribou Biosciences, Inc.$CRBU

Biotechnology

$1.54-4.94%

1Y-18.1%

29 posts+3%

Mixed sentiment

Caribou Biosciences chatter is mixed: bulls highlight strong CB-011 CaMMouflage Phase 1 clinical data in relapsed/refractory multiple myeloma with the company running a 250-patient randomized AID trial, and Rachel Haurwitz speaking at BIO Convention about expanding CAR-T access. Counter-voices express concern about the stock dropping to $1.69 with the company needing financing to fund Phase 3. With a small sample and execution overhang, the directional read is balanced.

Scribe Therapeutics Inc.$SCTX

Biotechnology

$30.54+7.38%

1Y+103.6%

48 posts+9%

Bullish sentiment

Scribe Therapeutics posters are running a fresh-IPO conviction thread. SCTX is Nasdaq-listed backed by LLY and SNY, closed an upsized IPO and concurrent Sanofi private placement raising ~$155.5M gross (9.867M shares at $15 plus a Sanofi purchase). Insider Form 4 activity shows Behzad Aghazadeh buying $36.12M on July 24, plus Orbimed and Director both $15M and 10% owner AH Bio $5M. Little bearish voice; the tone is 'follow the money.'

See the AI verdict on every ticker

Sentiment is what the crowd says. The verdict is the research behind it — fundamentals, filings, insider activity — on every name in this theme.

Gene Editing & CRISPR stocks trending on X

Gene Editing & CRISPR stocks trending on X

From chatter to a researched verdict — automatically.

We watch every day.

AI reads the crowd, in plain English.

AI validates with analyst-level research.

Free to sign in. Built for retail traders.

AI verdict on every ticker

Track this theme

Watchlists + Trusted Accounts

Gene Editing & CRISPR stocks trending on X